A phase II clinical trial of neoadjyvant chemoradiation therapy using Gemcitabine combined with IMRT for borderline resectable pancreatic cancer
Phase 1
- Conditions
- borderline resectable pancreatic cancer
- Registration Number
- JPRN-UMIN000010113
- Lead Sponsor
- Hepato-pamcreato-biliary Surgery and Transplantation, Graduate School of Medicine and Faculty of Medicine KyotoUniversity
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 37
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with lung fibrosis or interstitional pneumonia 2) Patients who can not underwent radiation therapy because of past radiation therapy 3) Severe co-morbid diseases 4) Intractable pleural and pericardical effusion, or ascites 5) Patients with other active cancers 6)Pregnancy or insufficient contraception 7) severe mental illness 8) Patients seems inadequate for this study by investigator(s)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Histological curative resection rate (R0 Ratio)
- Secondary Outcome Measures
Name Time Method pathological responce rate, progression free survival, over all survival, incident of adverse event, mortality